The global renal osteodystrophy market is anticipated to grow at a considerable growth rate during the forecast period. The renal osteodystrophy is a bone disease which occurs when kidneys are not able to maintain proper levels of calcium and phosphorous in the blood. It is more prevalent in the people living with kidney diseases and having regular dialysis. It is also prevalent in children which causes slow bone growth and deformities along with short stature. Renal osteodystrophy market is augmenting due to increasing kidney failure incidences all across the globe. It is due to the unhealthy lifestyle of the people such as consumption of alcohol and tobacco that increase the chances of kidney failure. Cost of dialysis and kidney transplant are high and lack of awareness among the people act as a major restraint towards the market gorwth. For instance, according to Central for Disease control and prevention, as many as 9 in 10 adults with CKD do not know they have chronic kidney disease, and nearly 2 in 5 adults with severe chronic kidney disease do not know they have chronic kidney disease.  

Moreover, according to Central for Disease control and prevention report published in 2021, more than 1 in 7, that is 15% of the US adults or 37 million people, are estimated to have chronic kidney disease. . Hence, the rising number of kidney diseases patients, technological advancements in the treatment of kidneys, and high blood pressure, contributes to the growth of the market. Apart from these, the increasing healthcare expenditure in major economies are expected to create new growth opportunities to the market. For instance, according to the US Renal Data System 2020 Annual Data Report, Medicare spending for beneficiaries with CKD ages 66 or older exceeded $70 billion in 2018. 

Impact of COVID-19 Pandemic on Global Renal Osteodystrophy Market 

The COVID-19 pandemic has a negative impact on the global renal osteodystrophy market. According to the report published by Kidney Medicine in April 2021, stated that acute kidney injury occurred in 36.6% of hospitalized patients and was particularly prominent in patients admitted to the intensive care unit or requiring invasive mechanical ventilation during the COVID-19 pandemic. The renal osteodystrophy treatment has been stopped, health systems have struggled to cope with the increasing spread of the infection and many clinics/wards have converted to COVID-19 units. Therefore, important disruptions occurred in the delivery of routine health services. Mobilization restrictions, problems in accessing healthcare facilities, and the effective role of nephrologists in combating the COVID-19 pandemic restricted the patient's access to the nephrologists.

Segmental Outlook 

The global renal osteodystrophy market is segmented on the basis on diagnosis method, and treatment. Based on diagnoses method, the market is bifurcated into bone biopsy, and blood test. Based on treatment, the market is bifurcated into hemodialysis, kidney transplantation, medication (cinacalcet, rocaltrol), and parathyroidectomy. 

Global Renal Osteodystrophy Market Share by Treatment, 2021 (%)

Hemodialysis is Anticipated to Grow at the Fastest Rate in Renal Osteodystrophy Market

Based on treatment, the hemodialysis segment is expected to hold prominent share during the forecast period. The growth is mainly driven by an increase in the incidence of hypertension and diabetes.  Moreover, the rise in the number of end-stage renal disorders (ESRD) patients and the shortage in availability of kidneys for transplants are considered to be the prominent factors for the growth of the market. For instance, according to the US Renal Data System 2020 report, nearly 786,000 people in the US are living with end-stage kidney disease (ESKD),with 71% on dialysis and 29% with a kidney transplant. Owing to the rise in the number of diseases, and the scarcity of kidneys for transplant, boost the growth of the market.

Regional Outlooks

The global renal osteodystrophy market is further segmented based on geography including North America (the US, and Canada Europe (Italy, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America).  The Asia-Pacific region is estimated to be growing at a considerable rate during the forecast period owing to the high development in government expenditure in the healthcare industry, rising prevalence of renal chronic disease and increasing lifestyle-related diseases in the region. Major economies contributing to the growth of the market in the Asia-Pacific region are China, India, and Japan.

Global Renal Osteodystrophy Market Growth, by Region 2021-2028

North America Region is Proved to be the Largest Region for Global Renal Osteodystrophy Market 

North America dominated the renal osteodystrophy market owing to the presence of a large pool of patients suffering from chronic kidney diseases, and the availability of advanced healthcare facilities and infrastructure mainly in the US and Canada. According to Pan American Health Organization, chronic kidney diseases (CKD), including acute glomerulonephritis, chronic kidney disease due to diabetes, and other chronic kidney diseases, are the leading causes of mortality and disease burden in the Region of the US in 2019. 

Market Players Outlook

The major companies serving the global renal osteodystrophy market are Amgen Inc., Asahi Kasei Corp., and B. Braun Medical, Baxter International Inc., DaVita Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2020, Fresenius Medical Care North America has expanded its partnership with Humana to designed for eligible Humana Medicare Advantage and commercial members with chronic kidney disease or end-stage kidney disease. In the evolution of renal disease care, the company offers best way to improve health outcomes and the patient experience is personalized coordination that meets the needs of each individual.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global renal osteodystrophy market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future. 
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.